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SUMMARY 
Background. Celiac disease is a widespread autoimmune disease diagnosed at increasing frequency. 
Celiac patients regularly attend medical services and present a benign course. The knowledge of 
clinical and biological factors predictive of malignant evolution is poor. Thus, management of such 
a large population of patients still lacks evidence-based criteria in order to target diagnostic 
strategies to the subgroup ”at-risk” to develop small bowel complications. 
Aim. To identify celiac patients’ characteristics associated to a higher probability of complicated 
course and to evaluate the role of available screening and diagnostic approaches and coming 
biomarkers for the early diagnosis of small bowel malignancies in celiac disease. 
Methods. A population-based registry (Varese province) was used to estimate the risk of intestinal 
lymphomas in undiagnosed celiac subjects, taking into consideration different settings of celiac 
prevalence and relative risks for intestinal lymphomas in comparison with the incidence of the 
lymphomas in the population. Treated celiac patients were selected on the basis of clinical flags of 
non-responsiveness or lack of compliance to treatment for targeted small bowel endoscopic 
examinations, evaluating the diagnostic yield of capsule endoscopy and double-balloon enteroscopy 
in the recognition of intestinal tumors at an early stage. miRNA profiles in type I and II 
enteropathy-associated T cell lymphoma were explored to identify eventual celiac related signature 
to be applied to subgroups of patients with different levels of risk for stratification purpose. 
Results. In the considered population (815,362 inhabitants), during a five years period, the relative 
risks of undiagnosed celiac disease for gastrointestinal B- and T-cell lymphomas ranged from 1.0 to 
2.0 for 1:100 celiac disease prevalence. In the selected series of 105 celiac patients, the diagnostic 
yield of capsule endoscopy and double-balloon enteroscopy for malignancies was 2.9%. When 
compared to the registered population, the relative risk for adenocarcinoma and neuroendocrine 
tumors in the studied cohort was 410 (CI 95% 102-1640, P<0.0001). Double-balloon enteroscopy 
was useful to histologically characterize even minor lesions detected at capsule endoscopy. A single 
miRNA (under patent) resulted upregulated in type I enteropathy-associated T cell lymphoma with 
confirmation at qPCR (p=0.0012). When mucosa specimen were evaluated, miRNA profiling of 
refractory patients was highly homogeneous (p=0.001 vs both type I and II enteropathy-associated 
T cell lymphoma).  
Conclusions. Undiagnosed/untreated celiac patients did not show a different risk of developing 
gastrointestinal lymphomas than the general population. Capsule endoscopy and double-balloon 
enteroscopy could be considered at an early stage in the diagnostic management of a subset of 
celiac patients at risk for small bowel malignancies. We expect to identify miRNA signatures as a 
novel biomarker predictive of disease aggressiveness to support the implementation of a 
personalized clinical approach, in order to optimize resources employment and, through a  timely 
pharmacological intervention, improve prognosis of these subset of celiac patients. 
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1.CELIAC DISEASE AND SMALL BOWEL COMPLICATIONS 
1.1 Celiac disease 
Celiac disease (CD) is an autoimmune disorder precipitated, in genetically predisposed subjects, by 
a known environmental factor, that is the ingestion of gluten. While in the past it has been usually 
considered a malabsorption syndrome affecting the children, CD is now recognized as a systemic 
autoimmune disorder with possible onset at any age.  
Gluten is the major storage protein of wheat and other cereals. Gliadin, the alcohol-soluble gluten 
fraction, and its undigested fractions are responsible for the immune response activation, which is 
mediated by both the innate and the adaptive immune systems. 
Such peptides (as an α-gliadin portion made up of 33 amino acids) pass the intestinal epithelial 
barrier and in the lamina propria interact with antigen presenting cells HLA class II DQ2 or DQ8 
restricted.  Type II transglutaminase deamidates gliadin peptides, increasing their immunogenicity. 
The adaptive response is mediated by CD4+ T cells with consequent release of proinflammatory 
cytokines (mainly interferon-γ). Due to the innate immune response, enterocytes express IL-15 
and NK-G2D intraepithelial lymphocytes exert cytotoxic effects on enterocytes. Moreover, crypt 
hyperplasia and villous atrophy develops a consequence of extracellular matrix proteinases 
activation. 
HLA-DQ2 or HLA-DQ8 is necessary but not sufficient condition for the development of CD. HLA 
genes contributes for less than 50% to the genetic substrate of CD, with other non-HLA genes 
perhaps contributing to the disease. Others unknown environmental factors, such as viral infection, 
may be involved in the pathogenesis. 
Prevalence of CD in western countries is about 1% in screening population studies. [1] The disease 
is recognized not only throughout Europe and in countries populated by persons of European 
ancestry but also in the Middle East, Asia, South America  and North Africa. The world distribution 
of CD seems to have followed the mankind wheat consumption and the migratory flows, registering 
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an increased frequency in many developing countries. It is mainly due to the Westernization of the 
dietary  habit, changes in wheat production and preparation, and also increased awareness of the 
disease.[2] 
Clinical presentation of CD varies according to age. Malabsorption symptoms and growth 
retardation represent common onset in infants and children.  
Among adults, two to three times as many women have the disease as men, probably reflecting the 
prevalence of autoimmune diseases. Mono-paucisymptomatic or silent presentation in adults 
include functional-like gastrointestinal symptoms, iron-deficiency anemia, unexplained 
osteoporosis or elevation of transaminases, recognition during  surveillance among first-degree 
relatives of CD patients and subjects with known CD-associated conditons (i.e. Down syndrome, 
type 1 diabetes). Classic onset occurs in the elderly too. Substantial proportion of patients are 
overweight. Persons with celiac disease have an increased risk of autoimmune disorders as 
compared with the general population. [3] Patients often have symptoms for a long time and 
undergo multiple investigatons before CD is diagnosed.[4] 
Diagnosis of CD relies on serology and duodenal biopsy, performed while the patient is on a gluten-
containing diet. Biopsy remains the mainstay for the diagnosis in the adulthood. [5] To state definite 
diagnosis of CD, villous atrophy is required (grade ≥ 3, according to Marsh-Oberhuber [6]). 
However, lesser degrees of damage (≥25 IELs but no villous atrophy) combined with positive 
serology may also represent CD. Serological detection depends on the presence of specific 
endomysial antibodies (EMAs), IgA anti-tissue transglutaminase antibodies (IgA-TG2) and/or 
deamidated antigliadin antibodies (DGP, either IgA or IgG isotype). IgG-TG2 is primarily useful in 
patients with known IgA deficiency. The prevalence of seronegative CD is 6–22% of all diagnosed 
cases. [7, 8] Biopsy of the duodenum for a diagnosis of CD should be performed irrespective of the 
prior performance of serological tests, if the patient exhibits symptoms or signs of CD, such as 
diarrhoea, weight loss or anaemia. [9]  
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1.2 Celiac disease and malignant complications 
The association between CD and cancer is long established. Cases of small bowel (SB) lymphoma 
were described in the presence of clinical manifestation of malabsorption in the first half of the 
twentieth century.[10]  In 1962, Gough firstly reported five cases of intestinal lymphoma in CD, 
hypothesizing a predisposing role of the enteropathy toward the malignant transformation.[11] 
Epithelial cancers of the gastrointestinal tract were incostantly reported in CD with higher 
frequency than expected and contributing to higher mortality rate in patients affected by CD.[12-14]  
Liver cancer has been isolatedly reported with a higher frequency in CD,[15] while incidence rate 
seemed to be reduced as far as breast cancer is concerned.[12, 16]  
Mechanism for the development of malignancies in patients with CD is not known: however, 
hypothesis involving increased intestinal permeability of environmental carcinogens, chronic 
inflammation, chronic antigenic stimulation, circulation of proinflammatory cytokines, alterations 
in the immune surveillance and nutritional deficiencies have been proposed. 
1.2.1 Enteropathy-associated T cell lymphoma and other lymphoproliferative disorders 
Enteropathy-associated T cell lymphoma (EATL) is a rare non-Hodgkin intestinal lymphoma. 
Estimated annual incidence rate is 0.5-1 per million people in Western countries. [17, 18] Peak of 
incidence is evident in the sixth decade of life. 
According to the WHO classification (2008), EATL is reported among the peripheral T cell 
neoplasms. Type I EATL has been described with either overt or clinically silent gluten-enteropathy 
and it is more spread in the European countries. Secondary EATL develops in adult patients 
previously diagnosed with CD, following a GFD who subsequently manifest exacerbation of 
symptoms. Onset of the complication most of times occurs during the first 5 to 10 years after CD 
diagnosis, but it has been reported in long-standing CD too. Primary EATL arises in subjects 
without a known history of CD. Serological tests may be helpful in identifying the associated 
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enteropathy even if antibodies may disappear at this stage. Type II EATL has a worldwide 
distribution, it is usually sporadic and it should be considered a separate entity.  
EATL represents about 35% of intestinal lymphoma. Preferential site is the jejunum, but it may 
develop in the ileum, lymph nodes, stomach and colon. Up to 25% of cases presents a multifocal 
distribution. As far as immunophenotype is concerned, type I EATL is characterized by CD3
+
,CD4
-
, CD8
-
,CD5
-
, CD7
+
,CD103
+
,CD56
-
,TCR+/ -cells, mainly CD30 positive. 
Systemic or B symptoms should be taken as alarm signs, although they are present in less than 30% 
of EATL.[19] Non response to GFD or new onset of diarrhea, abdominal pain and unexplained 
weight loss should raise the suspicion in patients on GFD. Recognition of primary EATL could be 
difficult due to low specificity of the clinical picture.  
EATL may represent the end-stage of a refractory course of CD, occurring mainly in type II RCD. 
Some CD patients complicating directly into EATL have been described,[20] while EATL has been 
described in only 2 patients with type I RCD.[21]  
Early studies indicated a relative risk for lymphoma in CD of the order of 50-100 but studies were 
conducted in tertiary referral centers and included patients with concomitant diagnosis of CD and 
lymphoma, introducing relevant bias as far as diagnostic ascertainment is concerned.[22-24] More 
recently, relative risk for gut lymphoma in CD has been estimated to be about 17 folds the risk of 
the general population as from case controls studies [25, 26] and up to 40 folds, when the 
association was evaluated in a prospective population-based study: Card found such a risk in the 
celiac population attending a secondary referral center with regular follow up, perhaps allowing an 
accurate detection of complication than in data obtained from population registry. Of note, 
malignant cases detected in the CD peri-diagnosis period were not included and patients were 
younger than in first studies.[16]   
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An increased risk for non-Hodgkin lymphoma (NHL) was attributed to CD patients too, as from 
Ema screening of newly diagnosed NHL in a case-control study, being estimated in about 3-
folds.[25] Population-based studies showed standardized incidence ratio between 6 and 12 [15, 16, 
27] and absolute rates of 8-13/10000 persons year.[16, 27, 28] Some limits may derive from studies 
having discharge diagnosis as inclusion criteria and therefore evaluating perhaps more severe 
inpatients. [15, 29, 30] Increased risk for NHL including both T-cell and B-cell types and occurring 
in both gastrointestinal and extraintestinal sites was reported. [30, 31] 
Prognosis of EATL is very poor and this is particularly evident when it develops in association with 
type II RCD, with a 5-year survival rate between 8 and 20% among patients with both EATL and 
RCD II.[32] 
A definite diagnostic algorithm in EATL has not been accepted yet. Computerized tomography or 
magnetic resonance enterography allow visualization of bowel wall thickening, intussusception, 
lymph nodes enlargement and cavitation, raising suspicion of RCD II or EATL. [33, 34] PET scan 
showed high sensivity but low specificity for the detection of EATL. [35] Imaging techniques have 
been integrated by the more recent introduction of enteroscopic tools (capsule endoscopy and 
device-assisted enteroscopy) for the visualization of SB mucosal alterations and histological 
characterization.  
Evidence-based data on EATL treatment are lacking due to low incidence of the disease and 
frequently poor nutritional conditions of the affected patients. First-line surgery has a prominent 
role for those patients presenting with complications at the onset, that is with obstruction, bleeding 
or perforation. Moreover, surgical approach often precedes medical therapy, according to the higher 
risk of such complications during chemotherapy.  
Standard-dose multidrug chemotherapy and, particularly, CHOP regimen represent the most 
common treatment choice for EATL, with the achievement of an overall 5-year survival of 9-
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22%.[19, 36] More promising results came from mainly restrospective, small sized studies 
exploring the role of high-dose chemotherapy followed by autologous stem cell transplantation 
(ASCT): CHOP has been traditionally adopted as first-line chemotherapy and BEAM (carmustine, 
etoposide, cytarabine and methotrexate) as conditioning regimen, respectively. The choice of a 
more intensive treatment should be based on an accurate selection of those patients who can tolerate 
it.    
1.2.2 Small bowel adenocarcinoma 
Malignant tumors of the small bowel comprise 3% of all gastrointestinal malignancies. Primary SB 
adenocarcinoma is the most common histological subtype, representing 35-50% of cases.  
According to the EUROCARE data, the estimated number of annual new cases of SB 
adenocarcinoma in Europe is 3600, with an estimated incidence rate of 5.7 cases per million 
persons. [37] 
Recognized settings for the development of SB adenocarcinoma are inflammatory bowel diseases 
(Crohn’s disease, celiac disease) and genetic syndromes including familial adenomatous polyposis, 
hereditary non polyposis colon cancer (HNPCC), and Peutz-Jeghers syndrome. Consumption of red 
or smoked meat, saturated fat, refine carbohydrates, alcohol, obesity and smoking have been 
suggested among possibly related behavioral risk factors.  
Presently, SB adenocarcinoma is reported to be the second most common malignancy (after 
lymphoma) in CD. One of the first descriptions reported a 8% prevalence of SB adenocarcinoma in 
CD population.[12] When SB adenocarcinomas were taken into account, a concomitant celiac 
enteropathy was observed in 13% of cases. [38] 
Relative risks of developing SB adenocarcinoma in CD were reported between 10 and 70. [4, 12, 
15, 31, 39] Some of the evidence comes from studies involving previous or concomitant diagnosis 
of malignancy and CD. [31] On the other hand, data showing a persistence of the risk of developing 
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intestinal adenocarcinoma during follow up period on GFD exist. [15, 40] The observation could 
support the idea that gluten avoidance could not prevent this complication. In line with this 
assumption, case reports highlights the chance of SB adenocarcinoma in patients with childhood 
onset and adequate treatment [41]  and in case of histologically proven CD remission. [42] 
Moreover, low incidence of the tumor makes observations inconstant about the association between 
the malignancy and CD, with population-based cohort studies not reporting such an increased risk. 
[16, 43] 
Most common site for SB adenocarcinoma is the duodenum (55-82%), followed by jejunum (11-
25%) and ileum (7-17%); however, in celiacs it is more frequently located in the jejunum.  
Pathogenic steps are not fully elucidated but an adenoma-carcinoma sequence hypothesis has been 
advanced. Microsatellite instability (MSI) has been documented in up to 60-70% of CD related 
intestinal adenocarcinoma [41, 44], locating CD among possible differential diagnosis when facing 
with SB adenocarcinoma with MSI. Aberrant methylation at CpG islands, an epigenetic 
phenomenon usually observed in tumors and other conditions like chronic inflammation, has been 
found in neoplastic (MINT and MGMT loci) and particularly (MLH1) in CD related neoplastic 
tissues, even if specificity is low. [41] APC mutation is less often observed than in colorectal 
cancer, even if an alteration of beta-catenin is probably involved. [45] 
Diagnosis is usually delayed due to aspecific clinical presentation, including vague abdominal pain. 
Thus, occlusion and bleeding frequently characterize the onset of the disease at an advanced stage, 
when an emergent surgical intervention is needed. 
 Treatment approach is based on surgery and curative resection is achievable in about 40-65% of 
cases. Given its infrequency, no clear data are available about the role of chemotherapy and/or 
radiotherapy in the adjuvant phase and indications are extrapolated from the experience on colon 
cancer. Accordingly, French recommendation included a fluoropyrimidine and oxaliplatin-based 
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chemotherapy after a curative R0 resection of a stage III adenocarcinoma and, optionally, for pT4 
stage II tumors (www.tncd.org). Five-year overall survival rate ranges from 14 to 33%, depending 
on tumor stage. 
1.2.3 Risk factors for  malignant complications 
A small subset of the large celiac population actually develops malignant complications. The 
knowledge of the demographic, clinical, behavioral characteristics with prognostic implications is 
still incomplete. A profile of the celiac patient with a higher probability to show a lack of response 
to GFD or to present a malignancy during the lifetime is presently only partially understood. 
Attempts to identify such an “identikit” should be pursued in order to orient diagnosis and 
management of celiac patients. 
Advanced age at CD diagnosis has been considered as one of the features possibly related to a 
different course of the disease. This can possibly be related to later introduction of GFD or, even 
more interestingly, to a different manifestation in the wide clinical spectrum of CD.  In fact, in the 
elderly clinical symptoms leading to recognition of the enteropathy could also be more pronounced, 
with classical presentation being more represented than in the adulthood. Observation of such a 
relationship between age at diagnosis and complicated course, [46] however,  has not always been 
confirmed.[47] The same work by Corrao et al. and other studies [48-50] outlined that overt clinical 
onset of the disease itself was more frequently associated with a complicated course than in case of 
paucisymptomatic clinical picture.  
On the other hand, when risk of malignancy was evaluated in the pediatric celiac population, both 
increased [9, 39, 51] and not increased risks [15, 27, 52, 53] were described. With this regard, data 
should be taken into consideration looking at follow up time duration: particularly, lack of evidence 
of malignancy could be ascribed to the fact that young patients did not reach in the follow up time 
the age in which these kind of tumors mainly develop.  
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Again, a protective role of GFD has been questioned since conflicting data are present as far as 
neoplastic risk during follow up of treated patients is concerned. Askling et al. showed a risk 
reduction over treatment periods,[15] while risk appear quite stable in studies by Biagi and Gao et 
al.. [29, 46] 
Similar considerations could be drawn from the observation of risk declining over calendar periods 
[15] or persisting over decades [29, 52]: interpretation of data should comprise possible beneficial 
effect of ongoing dietary treatment, not missing to consider the characteristic of the population over 
time. Actually, recognition of celiac disease in less severe cases or even in the absence of symptoms 
could have modified the overall clinical profile of the population and related prognosis. 
When the degree of villous atrophy was evaluated with respect to the risk of lymphoproliferative 
evolution, no correlation was found. [52] Moreover, an increased risk of NHL and mortality was 
described in patients with non atrophic SB inflammation: the observation is, however, of limited 
interpretative value, given the lack of characterization of such histological damage, with risk 
declining over 5 years (effect of introduced GFD? Acute transient inflammation?).  
A contributory effect of genetic predisposition is emphasized by the higher prevalence of HLA-
DQ2 omozigosity in patients with CD complicated by type II RCD or EATL. [54] Genotyping 
could then be part of the strategy to stratify patients according to their potential risk. 
Overall, evidence for a role of gluten avoidance in preventing complications is indirect and 
extrapolated from follow up observations of variable time duration, variable size of the studied 
population and with level of adherence to prescribed diet difficult to infer. [24, 47, 55] 
 
1.3 Non responsive and refractory celiac disease  
In the past, up to one fifth of CD patients were considered to be nonresponsive to GFD. Lack of 
agreement on the definition  of non-responsiveness was obviously one of the causes for such a high 
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percentage. Actually 7 to 30% of celiac patients refer persistence of symptoms on GFD, requiring a 
deep evaluation of the clinical presentation. Firstly, accuracy of CD diagnosis should be reassess, 
including histological specimen examination and HLA typing in questionable cases. Secondly, 
adherence to GFD should be investigated, since gluten assumption is the most common determinant 
for symptoms persistence and consultation of a dietician should be considered. Approximately up to 
5% of adult onset CD patients may have refractory celiac disease (RCD), defined as persistent 
symptoms and villous atrophy, despite scrupulous adherence to a gluten-free diet. The symptoms 
usually include diarrhea, weight loss, recurrence of malabsorption. Diagnosis of this condition is 
made after exclusion of concomitant extra-intestinal diseases (microscopic colitis, irritable bowel 
syndrome, pancreatic insufficiency), other small bowel disorders (lactose intolerance, bacterial 
overgrowth, inflammatory bowel disease, collagenous sprue, autoimmune enteropathy), including 
small bowel malignancies.  
Refractory celiac disease may be classified as type I, in which there is a normal intraepithelial 
lymphocyte phenotype, or type II, in which there is a clonal expansion of an abnormal 
intraepithelial lymphocyte population. This aberrant population of intraepithelial lymphocytes is 
characterized by lack of surface expression of CD3/T-cell receptor (TCR) complexes and of CD8 
but containing intracellular CD3 and a clonal rearrangement of the gamma chain of T-cell receptor 
(TCR).  
Practically, diagnosis of RCD has been proposed in case of symptoms relapse or continuation 
(chronic diarrhea and/or severe abdominal pain) with persistent malabsorption syndrome (decreased 
serum levels of iron, folate, vitamin B12 and/or calcium) in combination with histology showing 
persistent villous atrophy and increased numbers of IELs after 1 year of strict adherence to GFD, 
unless earlier intervention is required. RCD patients are almost always adults of 50 years and over. 
RCD II was defined by the presence of more than 25% CD103
+
 or CD45
+
 IELs lacking surface 
CD3/TCR complexes on flow citometry or >50% IELs expressing intracellular CD3 but not CD8 
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in formol-fixed sections and/or the presence of detectable clonal TCR rearrangement in duodenal 
biopsy specimen.[21]  RCD type II is associated with poor survival and between 45 and 60% of 
patients  die within 5 years, despite therapies. Transformation to overt EATL occurs in 50-60% of 
cases within 5 years.  
Ulcerative jejunoileitis was defined as more than three non-lymphomatous small intestinal ulcers, 
more than 0.5 cm sized, detected beyond the distal duodenum at push enteroscopy. [56] Ulcerative 
jejunoileitis may complicate and may precede the occurrence of overt T cell lymphoma in the 
presence of clonal IELs residents in intestinal ulcers.  
T-cell lymphoma complicating CD is considered to derive from the clonal intestinal IEL population, 
given the expression of the 7 integrin HML1 (CD103) in lymphomnatous T cells, as in normal 
IELs. [57] Moreover, sequence identity of TCR between overt lymphoma tissue and intestinal 
biopsies have been reported and supports the hypothesis. [58]  
From a therapeutic point of view, presently steroid therapy allows clinical improvement in the 
majority of patients; however, histological recovery occurs in 30-40% of subjects, without any 
impact on malignant transformation and with the onset of systemic complications drug-related. [59] 
When facing with steroid-resistance or steroid-dependence, Azathioprine, Ciclosporine and anti-
TNF have been used without benefit, due the lack of effect on the clonal lymphocyte population 
and, on the contrary, with possible increase of the risk of lymphoma development (as in the case of 
combined Azathioprine anti-CD52 therapy). Till now, scanty and conflicting data are available on 
anti-CD52 monoclonal antibody (alemtuzumab) utilization in RCD II.  Accurate identification of 
RCD II patients is needed in order to catch the chance of preventing EATL through early 
chemotherapy; cladribrine is a synthetic purine nucleoside showing good tolerance and moderate 
histologic and hematologic efficacy. [60, 61] High doses chemotherapies and autologous stem cells 
transplantation have been proposed in non responsive patients.[62, 63] 
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1.4 Markers of prognosis 
1.4.1 Celiac disease 
Recognition and prompt treatment of RCD is of utmost importance to ameliorate prognosis. 
Prediction of a complicated course would be necessary but not feasible, depending on the absence 
of markers of evolution. Thus, the importance of GFD response indicators should be stressed, in 
order to stratify patients and tailor targeted follow up programs. 
Repetition of serological tests on GFD treatment is a way of monitoring adherence and response to 
gluten avoidance. However, correlation between antibodies disappearance and mucosal intestinal 
recovery is poor.  Despite contradictory data,  positive serology is assumed to reflect some gluten 
intake and low TTG levels do not predict histological remission. [64] 
Specificity of persistent intestinal atrophy while on GFD is low and histological follow up of CD 
patients a prognostic indicator with poor accuracy. Actually, up to 70% of adult CD patients have 
been reported to maintain duodenal atrophy, [65] while a very strict minority of them will develop a 
complicated course. Guidelines recommend follow up duodenal biopsies in case of clinical non 
responsiveness, but routine upper endoscopy is not advised.  
1.4.2 Refractory celiac disease 
 The characteristics of the intraepithelial lymphocyte population have been evaluated as far as 
prognostic implications are concerned. The identification of monoclonal TCR rearrangement has 
been associated with an increased mortality risk. [66] Oligoclonal rearrangements, instead, were 
reported in patients showing a benign course, not differently from the subjects with polyclonal TCR 
gene rearrangements. The study from Rubio-Tapia et al. [67] highlighted that cumulative risk 
factors, such as monoclonality, older age, total villous atrophy and low hemoglobin and albumin 
levels predicted 5-year survival rates in RCD patients. In the work by Arguelles-Grande et al., [66] 
18 
 
evaluating 73 RCD subjects, again gender, age, degree of villous atrophy, duration of CD, presence 
of non-EATL lymphoma, clinical presentation at diagnosis did not anticipate clinical deterioration. 
After adjusting for age, gender and serology, detection of <50% CD3
+
 CD8
+
 IELs by 
immunohistochemistry was a strong predictor of clinical course, with 5-fold higher risk of 
worsening within 2 years.  
Most patients have negative CD serology at RCD diagnosis. However, persistence of CD related 
antibodies on GFD was observed in up to 30% of RCD patients. [21] Positive serology despite good 
compliance could be due to antibodies kinetics, presence of severe inflammation and  destructive 
lesions or presence of coexisting autoimmune disorders leading to false positive CD serology. 
Patients with positive serology have been reported to have a shorter time to clinical worsening in 
the comparison with patients who had negative serology. [66] However, patients with <50% CD3
+
 
CD8
+
 IELs and negative serology were at increased risk for anticipated clinical deterioration 
compared to patients with <50% CD3
+
 CD8
+
 IELs and positive serology who did not show an 
increased risk. In case of positive serology or polyclonal rearrangement with <50% CD3
+
 CD8
+
 
IELs, a bad clinical outcome could be due to gluten exposure and an increase of CD3
+
 CD8
- 
reflecting an expansion of  IELs. On the other side, aberrant α IELs could account for the CD8-  
IEL expansion of seronegative patients. Flow citometry could be of benefit in elucidating the 
charateristics of the phenotype of the IELs subgroups. 
Low haemoglobin levels and hypoalbubinemia may indicate a poor prognosis in RCD. [32, 67] 
Chronic elevated levels of transaminases were detected in about half of RCD patients in the series 
from Malamut et al.: in most cases, etiology remains unknown. [21] 
Coexisting diseases were found in the majority of RCD patients: autoimmune diseases were not 
showed to be associated with a higher risk of clinical worsening; when CD-related and non CD-
related diseases were looked at, infections were linked to a worse clinical outcome, while 
osteoporosis and microscopic colitis were reported in association with a lower risk of clinical 
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deterioration. Particularly, lymphocytic colitis was described in approximately one third of RCD 
patients (both type I and II). Lymphocitic gastritis was reported more frequently in type II than in 
type I RCD. 
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2. RISK OF SMALL BOWEL LYMPHOMA IN NOT RECOGNIZED CELIAC DISEASE: 
DATA FROM A REGISTERED POPULATION ACCORDING TO DIFFERENT COELIAC 
DISEASE PREVALENCE. 
2.1 Introduction 
Up to now the gluten-free diet (GFD) is the unique available therapy for coeliac patients and it is 
suggested to eliminate symptoms, normalize intestinal mucosa and, chiefly, prevent CD 
complications.[24, 53]  
The most fearful complications of CD are malignancies of the gastrointestinal (GI) tract, mainly 
non-Hodgkin and enteropathy associated T-cell lymphomas (NHL and EATL). Risk to develop GI 
lymphomas compared to the general population is different in the published studies. Moreover, 
some studies suggest that GFD and early diagnosis prevent the theoretical evolution of the chronic 
intestinal inflammation to the malignancy of the immunological cells by the elimination of the 
environmental stimulating antigen (gluten). [25, 53] Considering that CD is a common (1:100) and 
underdiagnosed disorder (1 out of 10),  [68-71]  the prevention of its harmful complications is a 
relevant topic with high social impact, involving a policy of early diagnosis and strict treatment 
compliance which imply social costs and personal sacrifice.  
The aim of this study is to estimate the risk of GI B- and T-cell lymphoma in undiagnosed CD in a 
province of the Northern Italy.  
 
2.2 Patients and methods  
2.2.1 Collection of data 
Data were collected from 1st January 1999 to 31st December 2004. The Varese Province was 
chosen because of the stability of its population and availability of cancer registry. 
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2.2.2 Cancer registry 
The Lombardy Cancer Registry is a population-based registry, covering all residents in the province 
of Varese, Northern Italy (mean 815,362 between 1999-2004). Collected data are tumor site and 
histological type according to ICDO3 classification (International Classification of Disease for 
Oncology, WHO, 2000), diagnosis date, hospital where the diagnosis was made and demographic 
information. The Registry is part of the network of the International Agency for Research on Cancer 
(IARC) from the seventies: its data were used for large international collaborative studies 
(Eurocare, Epic, Eurochip, Europreval). The registry uses all electronic source files (hospital 
discharge files, death certificates, regional health files, and pathology reports) and a proven-case 
generation methodology.[72-74]  
The completeness and diagnostic accuracy of the registry for the lymphoproliferative tumors is 
98,7%. [74]  
All gastric mucosa associated lymphoid tissue lymphoma (MALT) were excluded from the 
analysis. 
2.2.3 Selection of coeliac cases 
The cohort of patients with CD (ICD9-CM, International Classification of Disease, WHO 1997 – 
code 579.0) was obtained by identifying, through computerized search of the four Pathology 
Departments of the Province of Varese, histological reports from 1
st
 January 1999 to 31
th
 December 
2004. Only cases with a duodenal pathological report compatible with a grade 3 of the Marsh 
classification [75] were included.   
The CD prevalence is assumed stable in the period under study and in the 20 years before to take 
into account the latency between exposition (CD) and cancer. 
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2.2.4 Estimation of Lymphoma risk 
The expected cases of intestinal lymphomas in the coeliac population were estimated multiplying 
the risk of lymphoma in the general population for the number of coeliac prevalent cases, 
accordingly to different CD prevalence (1:50, 1:100, and 1:200) and adjusted for the reported 
relative risks of lymphoma in the coeliac patients. We assumed the simplifying conditions that the 
prevalence of CD in the Varese population was constant and the fraction of risk of lymphoma due 
to undiagnosed CD in the general population was that reported in the literature. [25, 29, 76-78] The 
risk of lymphoma was computed diving the number of lymphoma cases in the study period by the 
population under risk, that is to say the coeliac patients. Because the fraction of lymphomas 
attributed to CD is not precisely known, we estimated as all the GI B- and T-cell lymphomas were 
attributed to the CD and then other estimates with different assumption. 
Cases with coincident diagnosis of lymphoma and CD have been excluded from analyses. 
 
2.3 Results 
The population of Varese province had a 3.7% increase in the period of time considered; in 1999 it 
was composed by 806,323 inhabitants and in 2004 by 836,440 (mean number of inhabitants per 
year 815,362, 51∙7% females, mean age 43∙2).  
From 1999 to 2004 1,180 NHLs have been observed with a mean number per year of 197 (Table1);  
69.0% were extraintestinal B-cell NHLs, 19.0% GI B-cell NHLs, 11.0% extraintestinal T-cell 
NHLs and 1.0% GI T-cell NHL. Males represented the 54.5% (n=643) of patients with NHL, the 
50.6% of GI NHL, the 50.4 of GI B-cell NHL and the 55.5% of the GI T-cell NHL (no statistical 
difference between males and females). Twenty-nine gastric MALT in 1999, 10 in 2000, 11 in 
2001, 15 in 2002, 11 in 2003 and 15 in 2004, were excluded from our analysis. 
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The incidence (100,000 persons/year) of NHLs and subtypes was stable in the 6 years analyzed, 
being 24.1 for NHL, 4.8 for GI NHL, 21.4 for B-cell NHL, 4.7 for GI B-cell NHL, 2.7 for T-cell 
lymphomas and 0.2 for GI T-cell lymphoma.  
In the 6-years considered, according to the data from the Pathology Departments, a total of 6618 
subjects (M/F 2947/3671, mean age males 52.6 ± 20.0, mean age females 49.3± 21.0, total mean 
age 50.8± 20.1) underwent duodenal endoscopic sampling, and 326 (4.9%) resulted compatible with 
CD (mean yearly diagnosis 54, M/F 78/248, mean age males 30.6 ± 18.6, mean age females 31.8 ± 
17.7, total mean age 31.5± 17.9). The prevalence of diagnosed CD in the Varese population was 
0.04%. In coeliac group a single case of GI B-cell NHL was observed; however, the patient, a 59 
years old female,  had been excluded from the data analysis because diagnosis of CD and Ki-1 
positive anaplastic GI NHL were coincident. 
According to the real incidences of GI lymphomas observed in the investigated population, we 
applied different settings of CD prevalence (1:50, 1:100 and 1:200), as it should be from the studies 
investigating the presence of CD in the Caucasian populations, usually reported from 1:200 to 1:50. 
[69, 79-81]  
The first analysis is reported in Tables 2 and 3; in these tables are showed the expected cases of GI 
B- and T-cell NHLs in the coeliac cohort, according to the theoretical prevalence of CD in Varese 
Province, given different relative risks (RRs) derived from literature. Moreover, in the tables 
the impact (percentage) on the total number of observed GI NHLs is reported. In Tables 4 and 5 the 
risks to develop GI B- and T-cell NHLs in the CD theoretical population, calculated for different 
prevalence, are reported. The risks are defined for different percentages of CD associated GI B- and 
T-cell NHLs; thus, in every case of CD prevalence setting and percentage of NHLs directly induced 
by CD, the corresponding risk is showed. 
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2.4 Discussion  
The present study shows that undiagnosed/untreated coeliac patients have the same risk of 
developing GI lymphomas than the general population and thus this risk is not associated with 
gluten exposure. 
The rate of lymphomas registered in the Varese population is in accordance with the prevalence and 
incidence reported in other population studies. [82]  
Also the prevalence of diagnosed CD is in line with those described by other authors and, in 
particular, it is confirmed that only a few number (1:10) of coeliac patients receive a correct 
diagnosis. [83]  
Consequently, the largest part of the coeliac patients remain undiagnosed and untreated, continuing 
a regular dietary consumption of gluten, exposing them to a theoretical increased risk of developing 
lymphoproliferative complications [25]; in fact, the most qualified hypothesis suggests that the 
longstanding gluten exposure is the factor responsible for the development refractory CD, EATL 
and in general NHL. [58, 84]   
Different studies attempted to estimate the risk of lymphoma in diagnosed coeliac patients but 
results were not conclusive with a range of risks varying from no risk [55, 76]  to 300-fold increase. 
[4]  
 In our opinion, the main bias of the studies presenting extremely high risks to develop 
lymphoproliferative disorders in CD is the selection of the CD patients frequently derived from 
selected cohorts referring to tertiary centres and thus, not reflecting a general population “scenario”. 
To support this hypothesis, it is notable that some these cohorts often report also the association 
with other rare tumours as the oesophageal one suggesting an apical selection of the patients. [4]. 
Other studies enrolled cohorts deriving from hospitalized patients diagnosed in the seventies when 
CD was considered extremely rare and thus probably only heavily symptomatic patients with 
malabsorption received a correct diagnosis.[24] 
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 Moreover, CD and lymphoma are often diagnosed at the same time or within 3 years and a reverse 
causality could not be excluded and some other studies were conducted on small number of selected 
patients, or serologically diagnosed. [25] In fact, from most recent studies the RR is attested from 1 
to 10 in diagnosed CD and it seems especially attributable to patients with a late CD diagnosis after 
the 40 year of age. [9]  
From our study in Varese province, we can say that if all the observed cases of GI B- and T-cell 
NHLs were attributable to CD, the RR should be 200, 100 or 50 in populations with theoretic CD 
prevalence of 1:200, 1:100 or 1:50, respectively. However, we know that the proposed hypothesis 
“100% of NHL are associated to CD” is a paradox, very far from reality. 
Several studies, although with different methodologies and conflicting results, estimated the 
prevalence of CD in cohorts of patients affected by intestinal lymphomas. Majority of these studies 
identified patients with an already known diagnosis of CD and patients with a diagnosis of CD 
occurred when screened at the time of the lymphoma; taking into account the problems regarding 
the coincidental diagnosis, this latter group could be assumed as the prevalence of undiagnosed CD 
in the GI NHL population. The prevalence of hidden and undiagnosed CD in GI NHLs resulted 
2.0% in the study by Catassi et al. [25], 1.1% in a European multi centre study [77], 0% in studies 
conducted in Spain and Turkey [76, 78]; thus, it reasonable to assume a prevalence of undiagnosed 
CD among GI NHL ranging from 0% to 2%, probably close to 1%. [25, 29] Consequently, 
assuming that 1–2% of GI NHL is CD-associated, the RR of GI B- and T-cell NHL for coeliac 
patients ranges from 1.0 to 2.0 for a CD prevalence of 1:100 (Tables 2 and 3). Thus, the risk-year 
for 10,000 coeliac patients (prevalence 1:100) in Varese Province to develop GI B- and T-cell NHL 
varies from 0.46 to 0.93 and from 0.02 to 0.04, respectively. 
Our data demonstrate that the risk to develop a GI NHL in a theoretical population of undiagnosed 
and untreated CD patients is low, not higher than that observed in diagnosed and treated CD and 
lower than that present in some studies from the literature. [4] They are in line with the recent 
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results from Ludvigsson et al. [9] who show a 3- and 2-fold increased Hazard Ratio (HR) of 
lymphoproliferative malignancies in CD and duodenal inflammation respectively, and no risk for 
patients affected by potential CD (that is positive CD antibodies without duodenal histological 
damage). They suggest that the possible risk factor could be the inflammation itself and not CD. 
Although obtained with a different approach, our data are also in line with those presented by Lohi 
et al. [85] They evaluated the malignancy risk of undiagnosed CD by searching for CD specific 
autoantibodies in stored sera from a general population; in serologically positive patients they did 
not find an excesses of lymphomas or mortality and a 1% prevalence of CD was confirmed.  
 
The absence of a serologically screening of our population could be considered a point of weakness 
to investigate the hidden part of the CD iceberg; however, also the serological presence of CD 
autoantibodies could lead to some mistakes as showed in the study by Mearin et al. [77] where the 
50% of NHL patients with positive anti endomysium antibodies did not present a villous atrophy 
suggesting an higher rate of false positive in patients with haematological malignancies. 
For clinical purpose, to better define the meaning of the RRs showed above, if we consider a 
hypothetical Varese population composed by 99,000 healthy subjects (risk for GI NHL 4.8 per 
100.000 person/year) and 1000 undiagnosed and untreated CD patients (prevalence 1%) (risk for GI 
NHL 6.2 per 100,000 person/year) the non-CD subjects generates 4.7 GI NHL per year and the 
undiagnosed CD subjects generates 0.062 GI NHL; thus, all the CD population will take 16 years to 
develop only one GI NHL. 
Moreover, the present study induces some reflections on the role of gluten on the development of 
NHL in patients affected by CD. In fact, data about gluten exposure, measured as years of 
exposition or in terms of compliance to the GFD, are conflicting and scarcely precise because of 
lack of objective evaluation of completeness of the diet. [25, 53] Even if the widely accepted and 
logically intriguing idea that the gluten-induced chronic stimulation of immunological cells in the 
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intestinal mucosa of undiagnosed CD is at the basis of the development of a refractory state and 
NHL, looking at the evidence, more data are necessary to support this hypothesis. 
From a practical point of view, our study does not support the need to screen general population and 
asymptomatic subjects in order to prevent possible lymphomas and further data on the natural 
history of CD could be useful to program future national and familiar screening. 
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3. A CAPSULE ENDOSCOPY AND DOUBLE BALLOON ENTEROSCOPY SEQUENTIAL 
APPROACH FOR EARLY DETECTION OF GASTROINTESTINAL TUMORS IN 
CELIAC DISEASE: A PROSPECTIVE TRIAL 
3.1 Introduction 
The epidemiological characteristics of SB malignant complications and the knowledge of the 
supposed associated risk factors (age at CD diagnosis, mucosal healing, compliance to GFD) have 
led to the following considerations: (i) the risk of gastrointestinal malignancy in CD is not 
homogenously distributed; (ii) attention should be especially paid to those CD patients with 
demographic and clinical features that identify them at presumably higher risk of having a 
neoplastic complication; (iii) for such a subset of CD patients, an early diagnostic strategy of SB 
tumors is yet to be evaluated. 
The difficulty in SB exploration used to be the major problem for the early diagnosis of intestinal 
tumors. The introduction of SB capsule endoscopy (SBCE) and device-assisted enteroscopy (DAE) 
facilitated the study of the SB mucosa.  
Small bowel capsule endoscopy is a safe investigation allowing the direct visualization of the SB 
with a low invasive technology. Standard indications to perform SBCE are the investigation of 
obscure gastrointestinal bleeding, the assessment of SB lesions in known or suspected Crohn’s 
disease, screening and surveillance in familial polyposis syndromes, assessment and localization of 
SB  tumours; moreover, the enteroscopic techniques have been applied to both the diagnosis and 
management of patients with complicated CD, even if the data currently available are mainly 
obtained from retrospective investigations. 
Device-assisted enteroscopy is a system allowing the insertion of dedicated endoscopes through the 
SB. DAE is mainly represented by double-balloon enteroscopy (DBE): the system consists of a 
balloon assembled on the distal end of the enteroscope and a balloon on the overtube; its use 
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requires a series of steps employing a push and pull technique. Indications are almost the same of 
SBCE, with the additional chance of performing biopsies and treatment of a previously diagnosed 
disease (polipectomy, dilatation).  
Based on the aforementioned considerations, the present study aimed at prospectively evaluating 
the application of selection criteria (including the presumed clinical risk factors for SB 
malignancies in CD) and the diagnostic yield of SBCE and DBE, in the early detection of intestinal 
malignancies for this CD cohort.  
3.2 Methods  
3.2.1 Patients 
From June 10, 2011 to November 30, 2014, all consecutive CD patients attending the Center for the 
Prevention and Diagnosis of Celiac Disease – Gastroenterology and Endoscopy Unit at the 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Milan, Italy) were prospectively 
evaluated. According to the international guidelines, [5] CD diagnosis was based on the histological 
evidence of duodenal atrophy (a type 3 lesion according to the Marsh-Oberhuber classification).[6] 
The presentation type was categorized as classic (diarrhea, weight loss, longitudinal growth 
retardation), mono/paucisymptomatic (dyspepsia, anemia, hypertransaminasemia, osteopenia) or 
associated with the presence of dermatitis herpetiformis (DH). 
The patients were enrolled according to the following inclusion criteria: 
(i) presence of alarm symptoms/signs, either at diagnosis or during the follow-up; 
(ii) lack of compliance to GFD (defined as the conscious and regular gluten ingestion for at 
least 2 years); 
(iii) positive findings at radiological SB study. 
The study was approved by the local ethical and was carried out in accordance with the Declaration 
of Helsinky. Patients fulfilling the inclusion criteria gave their written informed consent to be 
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enrolled in the study and then underwent the following work-up: routine blood tests (i.e. full blood 
count, ferritin, transaminases, alkaline phosphatase, gamma-GT, glycemia, cholesterol, 
triglycerides, TSH); anti-endomisium and anti-transglutaminase antibodies; endoscopy of the upper 
GI tract with at least four oriented duodenal biopsies; determination of histological grading (Marsh-
Oberhuber’s classification) and CD3/CD8 immunoistochemistry; SBCE; DBE in case of positive 
findings at SBCE or when SBCE was contraindicated. Further investigations were carried out when 
clinically indicated. In details: TCR γ rearrangement analysis in case of suspected RCD or intestinal 
lymphoma; HLA typing to determine a genetic CD susceptibility; colonoscopy with multiple 
biopsies when suspecting colonic tumors, inflammatory bowel disease, or microscopic colitis; 
ultrasonography as a first step evaluation in case of abdominal symptoms. Furthermore, CT or MR 
enterography were performed for tumor staging or in case of intestinal obstruction. 
SBCE (Pillcam SB3, Given Imaging, Yoqneam, Israel) was performed after intestinal cleaning with 
a 3-litre polyethylene-glycol (PEG)-based solution (to be assumed the day before the examination) 
and overnight fasting. Patients with a cardiac pacemaker underwent examination under continuous 
cardiac monitoring. The Given Imaging recording system was positioned according to the 
manufacturer’s instructions; data were downloaded on a dedicated computer workstation and 
analyzed by a dedicated software (Given Imaging, Yoqneam, Israel). In those patients who had 
undergone major abdominal surgery or presented symptoms consistent with possible intestinal 
obstruction, SBCE was preceded by the evaluation of the intestinal canalization by patency capsule 
(Agile, Given Imaging, Yoqneam, Israel). As from Given Imaging specifications, the examination 
time with Pillcam SB3 was at least 9 hours. All registrations were conducted till battery exhaustion. 
The same physicians performed SBCE and DBE, and were in charge of CD management. In case of 
positive SBCE findings, DBE (Fujinon, Saitama, Japan) was then carried out. The following 
endoscopic features were considered for histological evaluation: mass lesions, ulcers, nodules or 
nodular mucosal patterns, extensive (beyond 30% of SB transit time) or patchy distribution of 
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atrophic features (mosaicism, scalloping, fissures). The route for insertion was planned according to 
the estimated site of the lesion as from SBCE (cutoff at 70% of capsule progression). Histological 
and immunohistochemical evaluations (CD3, CD8) were performed on the samples obtained from 
both the lesion and the adjacent mucosa.  
One-hundred and sixty-five non-celiac patients, matched for gender and age, and undergoing SBCE 
for obscure GI bleeding (overt or occult), were included as a control group for the SBCE diagnostic 
yield evaluation. The incidence of the tumor types diagnosed in the CD cohort was compared to that 
of a registered population (from the Lombardy Regional Cancer Database) of the Varese province 
(815,362 inhabitants), assumed as an index of incidence in the general population. Subject with CD 
were excluded from the above mentioned database. The tumor sites and histological types according 
to the ICDO3 classification (International Classification of Disease for Oncology, WHO, 2000) are 
reported in the database with a level of completeness and diagnostic accuracy of 98.7%. [74] 
3.2.2 Statistical analysis 
Statistical analyses were performed using SPSS ver.18. A P value of <0.05 was considered 
statistically significant (significance level for the tests: 5%, two tails). The sample size was 
calculated assuming a 5% prevalence of malignancies in the CD cohort. The normal distribution of 
the sample was verified through the Kolmogorov-Smirnov test. Continuous variables were analyzed 
with the ANOVA Oneway variance test or with the non-parametric Kruskal-Wallis test. The 
significance level was further verified by multiple comparison analysis (Turkey or Mann-Whitney’s 
test). Categorical variables were compared with the X² or Fisher’s exact test. 
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3.3. Results 
3.3.1. Patients profile 
One hundred  and five consecutive patients were enrolled (20 males); mean age at diagnosis was 
39.3±18.2 years, mean age at enrollment 46.8±14.0. When first diagnosed, 73 patients (69%) 
showed a classic clinical presentation, 28 (27%) were mono/paucisymptomatic and 4 (4%) had DH. 
Twelve cases (11%) tested negative at serology for CD: three had a selective IgA deficiency, and all 
presented DQ2 and/or DQ8 haplotypes. The clinical and demographic characteristics of the enrolled 
subjects are detailed in Table 6. 
Overall, the present series involved (i) seven patients (7%) with positive findings at trans-sectional 
imaging examination, (ii) 16 patients (15%) poorly compliant to GFD, and (iii) 82 (78%) having 
alarm symptoms or signs; this latter group included 29 patients with iron deficiency anemia, 6 with 
B symptoms consistent with hematologic disorders, and 47 with severe gastrointestinal symptoms.  
Eighty-six subjects (82%) entered the study after at least one year on GFD: among them 51 (49%) 
showed duodenal atrophy (Marsh-Oberhuber grade 3) at the follow-up histological evaluation. Six 
patients had type I RCD and six were diagnosed with type II RCD. 
3.3.2. Endoscopic findings 
One hundred and sixteen capsule endoscopy investigations were performed (11 patients underwent 
examination twice, due to follow up indication or incomplete small bowel exploration in nine and 
two cases, respectively). Capsule swallowing was uneventful in 115 cases (99%), whereas in a 
single one the capsule was endoscopically positioned in the duodenum since the first attempt failed 
due to a bulky gastric bezoar. One patient did not perform SBCE but directly underwent DBE due 
to a suspected intestinal obstruction. Capsule evaluation was completed in 99 cases (94%). 
Registration was stopped in the stomach in one patient with a gastric source of bleeding. The mean 
SB transit time was 266±93 min and it resulted slower in the RCD group (333±102min, P=0.01). At 
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SBCE mucosal abnormalities were detected in 71 capsule examinations (68%): in detail, a jejunal 
stenosis (adenocarcinoma), three ileal submucosal bulges (neuroendocrine tumor in one case),  a 
gastric bleeding mass (adenocarcinoma), granular gastric mucosa (a MALT lymphoma), SB 
mucosal nodular alterations (n=2), SB small erosions (n=15) or ulcers (n=4) and intestinal mucosal 
atrophy (n=44). SBCE retention was observed in the patient with jejunal stenosis and capsule were 
retrieved during subsequent surgical intervention.  
Overall, 16 patients underwent DBE due to positive findings at SBCE (following the evidence of 
extensive or patchy distribution of mucosal atrophy in seven cases, severe ileal nodularity in two, 
ileal ulcers in two patients, submucosal bulging in three cases) or when SBCE was contraindicated 
for suspected obstruction (one case). DBE and histological evaluation led to the diagnosis of a 
neuroendocrine tumor and a jejunal adenocarcinoma in the latter two patients (tumor diagnosis in 
12% of total DBE examinations). In a single case a mild-post DBE pancreatitis was observed.  
Colonoscopy was performed in 71 patients (68%), with detection of small non-dysplastic polyps in 
four cases and microscopic colitis in other five cases (5%). 
3.3.3 Comparison with control groups and risk factors 
In this group of celiac patients, the diagnostic yield of SBCE and DBE for malignancies was 2.9%. 
When the SB was investigated with SBCE for obscure gastrointestinal bleeding in non-celiac 
patients, tumors were detected in 0.6% (P=NS). 
When considering the registered population of the Varese province, the incidence rate of SB 
malignancies (adenocarcinoma and neuroendocrine tumors) was 2/100,000 inhabitants per year. As 
from the results of the present study, the calculated incidence rate of the same SB tumors in CD 
selected patients was 836/100,000 inhabitants per year. Accordingly, when compared to the 
registered population, the relative risk for SB malignancies in the selected CD cohort was 410 (CI 
95% 102-1640, P<0.0001). 
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The diagnosis of SB malignancy was not associated with gender or GFD compliance (P=1, Fisher’s 
exact test). Similarly, no association was found between a malignancy diagnosis and the presence of 
duodenal atrophy (P=1). Evidence of SB tumors was more frequent in the first year after diagnosis 
(P=0.0001). A trend toward an association between SB malignancies and the presence of anemia 
was observed (P=0.09, Fisher’s exact test; hemoglobin levels in malignant cases vs. patients with 
negative neoplastic findings, P=0.05). 
3.3.4 Patients follow-up 
Enrolled patients underwent clinical follow-up (twice a year) for a mean period of 20±13 months 
after SB evaluation, according to their entry date. Patients with negative neoplastic findings at 
enteroscopy did not present new symptoms or SB complications at follow-up. The described cases 
of SB malignancies were negative for disease recurrence after 29, 41, and 19 months, respectively. 
Exitus was reported at follow up in a 69 years old patient due to acute cardiac failure; one patient 
died 5 years after the diagnosis of type II RCD due to secondary multi-organ failure.  
 
3.4 Discussion 
The present study was aimed at evaluating the selection criteria associated with increased risk of SB 
malignancies in CD patients and the use of SBCE and DBE for the detection of such malignancies. 
In that context, SBCE and DBE allowed to diagnose three SB cancers: two jejunal adenocarcinoma 
and an ileal neuroendocrine tumor. As tumor incidence is not homogeneous in the CD population 
and the diagnosis of this complication is often late and associated with a poor prognosis, the 
identification of the subset of CD patients deserving an early diagnostic approach is mandatory and 
even more urgent based on the availability of new high-performing tools for SB examination. 
Small bowel capsule endoscopy has been considered of relevance in the evaluation of CD patients 
[18,19]. Available data on the SBCE use in a CD population are negatively influenced by the 
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retrospective design of the majority of the studies. Presently, the surveillance of RCD patients 
represents the main indication. Capsule endoscopy has proved to be useful in detecting enteropathy-
associated T-cell lymphoma (EATL) and ulcerative jejunoileitis among RCD patients [20-22]. 
When the SBCE examinations in treated symptomatic CD patients were reviewed,  diagnostic yield 
for ulcerative jejunoileitis and SB malignancies (EATL, adenocarcinoma) was 4.8% and 6.25% in 
the series of 42 and 48 patients, respectively [21,23,24]. In a further study by Maiden [25] nineteen 
CD cases were analyzed showing in two patients multiple ulcers consistent with ulcerative 
jejunoileitis, although no histological data were reported. Small isolated ulcers were detected in 3 
out of 50 CD patients in the study by Collin et al. [21] but, similarly, no histological data are 
available. Ulcerative jejunoileitis is arbitrarly defined to date as the finding of at least three jejunal 
ulcerations at enteroscopy.  [26] The suspicion of lymphomatous complications is considered if 
strictures and/or multiple ulcers are observed. Little is known about the predictive value of minor 
mucosal lesions detected at SBCE. Device-assisted enteroscopy is the only technique that allows for 
the adequate sampling of the SB when facing with mucosal lesions detected at SBCE, but little is 
known about the SBCE-DBE sequential use in patients with somewhat complicated CD. 
Small bowel capsule endoscopy has been evaluated by Culliford et al. [27] in CD patients showing 
the persistence of gastrointestinal symptoms, history of SB cancer, long standing CD with lack of 
dietary compliance and/or iron-deficiency anemia not responsive to oral supplementation. Forty-
seven patients on gluten free diet were studied with evidence of ulcerations in 21 cases, nodularity 
in six and cancer, polyp, stricture, intussusception and submucosal mass in one case, respectively. 
A prospective study has recently evaluated the use of SBCE in equivocal CD cases and 69 
symptomatic CD patients undertaking gluten free diet: in the latter cohort SBCE was positive in 
eight patients (mass lesion, extensive atrophy, ulcers); push or DBE enteroscopy confirmed the 
diagnosis of two EATL, four type I RCD, one ulcerative jejunoileitis; the polypoid mass at surgical 
removal was fibroepithelial [28]. 
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In the present series three tumors were detected among the patients enrolled with iron deficiency 
anemia. Indeed, the results strengthen the relevance of unexplained iron deficiency anemia as an 
alarm sign in  CD patients too, especially when severe and/or unresponsive to both gluten free diet 
and oral iron supplementation. In addition to a selective iron deficiency due to malabsorption, 
anemia could indicate a concomitant disease either at CD diagnosis or during an on-going gluten 
free regimen. 
The association of neuroendocrine tumors and CD is doubtful. If the hyperplasia of entero-
chromaffin cells has been demonstrated in CD [29] only case reports have been published 
describing CD subjects with neuroendocrine tumors. From this point of view, the finding of a 
neuroendocrine tumor in our series can be considered sporadic rather than a CD complication. 
The presented cases of SB tumors detected by SBCE and DBE had a favorable prognosis, when 
compared to literature data, supporting the impact of early diagnosis. 
Interestingly, SB malignancies were detected in patients diagnosed in adulthood (at 48, 31 and 38 
years respectively), in line with the large Swedish population-based study [3]. No malignancies 
were detected among non-compliant patients, even if the limited size of this subgroup precludes any 
definite conclusions. The high frequency of tumor diagnosis in the first year after CD diagnosis may 
reflect ascertainment bias, but it also represents the need for close follow up of those patients 
without a prompt response after starting GFD. 
Computerized tomography enterography and magnetic resonance enterography (a radiation-free 
technique that is advisable in young prevalently female cohorts) have showed an improved accuracy 
in visualizing the SB wall. On the other hand, the growing use in the last decade of SBCE and 
device-assisted enteroscopy has enabled the direct visualization and histological study of  SB 
mucosa. As a consequence, while a suitable accuracy for SB tumors has been described for the 
radiologic techniques, enteroscopy can better detect small lesions, confined to the mucosal layer 
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[30-32]. Since the expected SB complications in CD (namely ulcerative jejunoileitis, lymphoma and 
adenocarcinoma) share a mucosal origin, endoscopy appears the most appropriate approach when 
looking for any early stage SB malignancies.   
Small bowel capsule endoscopy was followed in two cases by the diagnosis of a gastric 
adenocarcinoma and a gastric MALToma, respectively. This is in line with the known possible 
occurrence at SBCE of findings related to the upper or lower gastrointestinal tract, missed by 
conventional endoscopy.   
Double-balloon enteroscopy was performed in 16 patients following SBCE, with the diagnosis of a 
neuroendocrine tumor despite negative findings at computerized tomography enterography. It is 
worth noting that to date a standardized classification of the endoscopic appearance of the early-
stage neoplastic SB mucosal lesions is missing. In case of nodular mucosal alterations, extensive 
and/or distal patchy atrophy, ulcerative lesions at SBCE in patients with clinically suspected RCD 
or intestinal lymphoma, DBE was planned and the histological excluded an underlying neoplasia. 
Thus, the poor predictive value of SBCE represents a major limit, suggesting that better 
understanding of the endoscopic appearance of early stage malignant lesions is needed. One patient 
with contra-indications to SBCE underwent DBE with evidence of jejunal adenocarcinoma. 
The enteroscopic techniques applied to our series showed a high diagnostic yield (even if not 
statistically significant in the comparison with non-CD patients undergoing SBCE for obscure 
gastrointestinal bleeding), presumably confirming an increased baseline risk in the selected cohort. 
When the incidence rate of SB malignancies was compared to that observed in the registered 
population of the Varese province, the calculated relative risk for intestinal malignancy in the 
selected CD patients was 410 (CI 95% 102-1640, P<0.0001). 
 However, when looking at these data a referral bias should be taken into consideration, as our 
patients were enrolled among those attending a tertiary center, i.e. in a cohort already selected rather 
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than in an unselected CD population. Another possible bias would be the presence in the Varese 
population of hidden CD cases, but, as previously demonstrated [9] this would not be expected to 
influence the results.  
As far as diagnostic accuracy is concerned, the high diagnostic yield of SBCE and DBE for tumors 
is worth noting together with the high number of patients undergoing DBE in the present series. 
Furthermore, close follow-up has not evidenced other tumors previously undetected.   
The present study represents a prospective attempt at the early detection of SB malignancy in 
complicated CD. Further research on the identification of the clinical and endoscopic characteristics 
of the “at risk profile” is needed. 
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4. DOUBLE-BALLOON ENTEROSCOPY IN CELIAC DISEASE: EXPLORING 
INDICATIONS AND DIAGNOSTIC GAIN IN THE EXPERIENCE OF TWO EUROPEAN 
TERTIARY REFERRAL CENTERS 
4.1 Introduction 
Enteroscopic techniques as device assisted enteroscopy (DAE), usually preceded by small bowel 
capsule endoscopy (SBCE), are a valuable tool for the study of the small bowel (SB) and for the 
diagnosis and treatment of SB diseases.  Mucosal lesions described and localized at SBCE can be 
then histologically characterized or treated by DAE. The described stepwise approach has been 
recognized as cost-effective in the management of patients undergoing SB evaluation for obscure 
gastrointestinal bleeding; at present, however, data in patients with celiac disease (CD) are only 
scattered.[86, 87]  
The follow up of a known refractory state represents the most frequent indication to SB endoscopic 
investigation in CD population.[88]
,
[89] Apart from this, the selection of celiac patients who 
deserve an accurate work-up for suspected SB malignant complications is still based on clinical 
experience, since evidence-based data are lacking.  
Notwithstanding a growing experience with SBCE in complicated CD patients, the actual 
agreement in the definition of related mucosal alterations is still low[90] and the  clinical relevance 
of subtle abnormalities is unknown, making histological sampling obtained with DAE mandatory.  
According to the present knowledge, celiac enteropathy is characterized by aboral decreasing 
severity of the intestinal damage but less is known concerning the distribution of mucosal lesions 
during GFD.[91]
,
[92] Noteworthy, EATL occurs more frequently distally in the small bowel[93] 
and also in the presence of non atrophic lesions in the adjacent mucosa.[94]  
Again, ulcerative jejunoileitis (UJ) has been arbitrarily defined by the presence of at least three 
mucosal ulcerations at enteroscopy;[56] however, the poor specificity of the endoscopic finding  
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requires histological integration to make a correct diagnosis (EATL, Crohn’s disease, infectious or 
drug related conditions).   
In line with these assumptions, we should consider (a) a complete longitudinal exploration of the 
SB is necessary in complicated CD patients; (b) a non atrophic duodenal histology could 
underestimate the presence of SB complications; (c) SBCE represents a well tolerated diagnostic 
tool in this context but histological examination through DAE is often needed to understand the 
possible pathologic meaning of the detected findings. 
All in all, the sequential use of SBCE and DAE is a potentially useful strategy in complicated CD, 
providing that proper indications to enteroscopy are acknowledged and applied. 
Present series was aimed at evaluating, in CD patients investigated for suspected SB complications, 
the  usefulness of DBE and the predictive value of the related SB endoscopic features. 
 
4.2 Methods 
4.2.1 Patients 
Celiac patients undergoing DBE between 1
st
 February 2009 and 31
th
 May 2014 at the Center for the 
Prevention and Diagnosis of Celiac Disease at the Fondazione IRCCS Ca’ Granda Ospedale 
Maggiore Policlinico Milan, Italy and Gastroenterology and Liver Unit, Royal Hallamshire 
Hospital, Sheffield, UK were retrospectively evaluated. All patients have been diagnosed as celiacs 
according to the histological evidence of duodenal atrophy [5] and had undergone SB evaluation in 
order to exclude intestinal complications. Poor adherence  to GFD was defined as regular and 
conscious ingestion of gluten for at least one year. 
The study was approved by the Ethical Committee (approval n° 2271). 
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Prior to DBE, SBCE  (Pillcam SB2, Given Imaging, Yoqneam, Israel) was performed when 
feasible. In cases of suspected bowel obstruction (previous major abdominal surgery, symptoms 
suggestive for altered intestinal canalization), SB patency was preliminary tested with Agile capsule 
(Given Imaging, Yoqneam, Israel). The test was considered negative for obstruction if the 
degradable capsule was retrieved undamaged and in the absence of gastrointestinal symptoms.  
In cases of positive findings at SBCE or when capsule endoscopy was contraindicated, DBE 
(Fujinon, Saitama, Japan) was carried out. The route of insertion was established according to the 
localization of the lesion at SBCE (cut-off at 75% of capsule progression).[95] Double-balloon 
enteroscopy was performed under conscious sedation. In presence of significant comorbidity, an 
Anaesthetist was actually present. Mucosal sampling from the targeted lesion and the adjacent 
mucosa was performed for histological evaluation and TCR gamma rearrangement.  
Radiological investigations (SB targeted ultrasound, computed tomography enterography, magnetic 
resonance enterography) were reported when carried out. 
Demographic data of the studied cohort were compared with a database of 1000 non complicated 
celiac patients attending the Center for the Prevention and Diagnosis of Celiac Disease, Milan. 
 4.2.2 Statistical analysis 
All the assumptions were verified using SPSS ver. 18 (IBM SPSS, La Jolla, CA), and a P value 
<0.05 was considered as statistically significant (significance level of the tests 5%, two tails). 
Continuous non parametric variables were analyzed with the Mann-Whitney’s test. Categorical 
variables were compared by 2 or Fisher’s exact test. Data were expresses as mean (± SD). 
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4.3 Results 
4.3.1 Patients 
Twenty-four CD patients (12 males, p=0.01 vs control database) underwent DBE. Both mean age 
(years) at CD diagnosis 37 (±20) vs 27 (±18) and at SB evaluation 47 (±15) vs 38 (±13) were 
significantly higher in the DBE group compared to controls (p<0.01). The body mass index (BMI) 
of the enrolled patients was 21 (±4) kg/cm
2
 (Table 6). 
Four patients were negative for celiac serology at diagnosis. HLA class II determination, anti-
enterocytes antibodies serum immunofluorescence, fecal and blood tests to exclude infective 
etiologies, endoscopic and imaging studies in order to differentiate inflammatory and neoplastic 
causes of villous atrophy were performed in these patients. Sixteen patients were diagnosed due to 
classic symptoms and eight patients were paucisymptomatic. Overall, poor adherence  to a GFD 
was registered in seven patients. Median duration of follow up after CD diagnosis was 1.75 years 
(range 0-70).  
4.3.2 Endoscopic studies 
Twenty-seven DBE were carried out. Indications to SB evaluation were (I) the follow up of a 
known RCD (n=9), (II) suspicion of SB complications due to (IIa) gastrointestinal symptoms (n=6), 
(IIb) severe iron deficiency anemia (n=6) and (IIc) long standing lack of dietary adherence (n=3). 
All DBE were performed after SBCE, according to the presence of mucosal alterations at SBCE, 
except for two cases (due to symptoms suggestive of bowel obstruction). Oral steroid therapy was 
ongoing in five RCD patients at the time of SB evaluation; four of these patients  were 
concomitantly given Azathioprine. 
Small bowel capsule studies were preceded by patency capsule evaluation (Agile) in seven cases: 
capsule retrieval was not possible in one patient who reported abdominal symptoms during the test. 
Magnetic resonance enterography and DBE from both approaches were performed in the patient 
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with negative results. Small bowel capsule exploration was incomplete in six patients (33%): one of 
these cases presented with a stricturing mass and other four patients had RCD (incomplete SB 
capsule evaluation in 44% of RCD cases; p=0.18, Fisher’s exact test). Mean SBCE transit time was 
281 (±109) minutes. No cases of retention were registered.  
Double balloon enteroscopy was performed via the oral route in 16 cases, with a mean insertion 
depth of 223 (±111) cm. Eleven enteroscopies were performed from the anal approach (three 
patients underwent both approaches, with the achievement of an “end to end” exploration in one). 
In one case DBE was not feasible due to the failure of the cannulation of the ileo-caecal valve. The 
mean length of the SB explored via the anal route was 122 (±106) cm. Mean  duration time of DBE 
for both antegrade and retrograde approach (with no difference between the two) was 68 (±20) 
minutes. A case of mild post-DBE pancreatitis was observed in one patient (female, 36 year old, 
BMI=18). 
4.3.3 Small bowel findings 
A diagnosis of jejunal adenocarcinoma was made in two patients, one from Sheffield and one from 
Milan. In the first case the mass lesion was firstly detected at SBCE. In the second patient, a 
segmental bowel thickening with contrast enhancement was described at magnetic resonance 
enterography and DBE confirmed a jejunal stenosis. Mucosal sampling of the adjacent mucosa 
showed atrophic features in both patients (grade 3a and 3b lesions respectively, according to Marsh-
Oberhuber classification).[6] An ileal neuroendocrine tumour was identified at SBCE and DBE in 
the terminal ileum. All the three patients presented with iron deficiency anemia.  
Six cases with ulcerative lesions were described. Three of these patients were classified as type II 
RCD, with monoclonal pattern at TCR gamma rearrangement (Figure 1A). Minute whitish raised 
patches were observed at enteroscopy in the proximal and mid SB in two type II RCD patients 
(Figure 1B).  
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In a patient not adherent to GFD, SBCE showed multiple small erosions in the distal ileum and 
histological evaluation supported the hypothesis of Crohn’s disease, according to the presence of an 
inflammatory infiltrate deep in the submucosa and focal cryptitis.  
In two patients poorly compliant to GFD, a skipped distribution of mucosal atrophy was observed, 
with involvement of the jejunum and relative sparing of the duodenum. Moreover, an irregular, 
patchy distribution of atrophic features was described in two GFD treated patients who underwent 
enteroscopy due to severe gastrointestinal symptoms, after a short period on GFD (four months) 
(Figure 1C).   
Small bowel imaging was performed for diagnostic completion purposes in fifteen cases 
(computerized tomography and magnetic resonance enterography in nine and six patients, 
respectively). Indications were a refractory state (n=5), gastrointestinal symptoms (n=6), anemia  
(n=3), GFD adherence (n=1). Computerized tomography enterography (CTE) was negative in the 
patient with confirmed ileal neuroendocrine tumour, 1 cm diameter. Four patients presented a 
jejunoileal fold pattern reversal; three of these patients also underwent SBCE, with the evidence of 
atrophy-related features extensively involving the SB (more than one third of the SB length). For 
small bowel findings in single patients see table in Supplemental Digital Content 1. 
4.3.4 Follow up 
Double-balloon findings induced a modification of patients management in eight cases (33%), as 
surgery was planned in the three neoplastic cases, steroidal regimen was prescribed in four with 
persistent gastrointestinal symptoms despite GFD and mucosal atrophy, after having excluded of 
the presence of lymphoproliferative disorder) at SB sampling; finally, Azathioprine was added in a 
patient with steroid-dependent RCD. 
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 Patients underwent follow up with regular clinical controls for a median time of 21 months (range 
0-60). Two patients died at follow up, due to multi-organ failure in type II RCD and severe cardiac 
failure, respectively.  
 
4.4 Discussion 
Data from present study clearly support the clinical usefulness of DBE to identify SB complications 
in CD.  In fact, DBE enabled us to early diagnose SB tumours (two jejunal adenocarcinomas and an 
ileal neuroendocrine tumour) as well as to histologically rule out malignancies in mucosal lesions 
detected at SBCE. This is the first series evaluating the role of DBE in patients with complicated 
CD. A single study had previously investigated the diagnostic gain of DBE in RCD, and in their 
selected cohort Hadithi et al.[94] described EATL in patients presenting with  multiple SB ulcers 
and stenosis. Moreover, no malignant complications were detected in this series in the presence of 
minor endoscopic findings, such as flattened villi, loss of folds, scalloping, nodularity. Ulcerative 
lesions and stricturing with associated mucosal flattening and nodularity were the reported features 
of EATL in case reports in which diagnosis was performed by enteroscopic tools.[96]
,
[97] On the 
other hand, when SBCE was performed in patients with known gastrointestinal lymphoma, slight 
mucosal alterations (villous atrophy, ulcerations, plaques, white villi) were described.[98] Multiple 
polyps and mucosal granularity were detected by DBE in the SB of subjects affected by 
gastrointestinal lymphoma; these “diminutive lesions” were reported to occur mainly in the  
follicular and MALT lymphoma histological type.[99] Thus, the comprehension of the clinical 
predictive value of SBCE findings is presently poor and standardized indications to DAE are 
lacking, especially as far as an early diagnosis of EATL is concerned. 
In  our study cohort, DBE was performed for histological definition of lesions detected at SBCE or 
when capsule endoscopy was contraindicated due to obstructive symptoms. Male sex and older age 
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were more frequent in the cohort of CD patients with a suspected complicated course in comparison 
with the “control” population represented by non complicated CD patients on GFD. Age at 
diagnosis has already been reported as a “risk factor” for a reduced response to GFD, even if data 
about possible reasons for that, such as gluten exposure, have not been clearly elucidated.[15]
,
[100] 
Among the patients undergoing DBE in the two referral Centers, the most common indication was 
the follow up of a known refractory state. Indication to enteroscopy in the three patients with a 
subsequent diagnosis of SB malignancy was persistent iron deficiency anemia despite ongoing 
adherence to GFD; therefore this finding should be interpreted as a possible sign of a complicated 
course. All the three neoplastic patients had a favourable staging, further supported by the  curative 
surgery without need for any additional therapy and lack of recurrences at follow up. 
 In the patients with type II RCD, i.e. the condition associated with the higher risk of EATL, SBCE 
detected mucosal alterations (raised patches, ulcerations) and DBE was carried out aiming at ruling 
out a malignant evolution. Noteworthy, the prognosis of intestinal lymphoma is usually very poor 
due to the advanced stage at diagnosis, which is the main determinant for the unsatisfactory  low 
therapeutic effectiveness.[101] Accordingly, any effort should be made to realize a prompt 
recognition of the disease. In this context, until recent times, main limitation was represented by the 
difficulty in exploring the small bowel. With the availability of the enteroscopic techniques, the 
present main focus is the identification of the SB mucosal findings unveiling early stage malignant 
lesions and/or alterations associated with subsequent malignant evolution (premalignant lesions), 
but the characteristics of these “alarm endoscopic features” are not defined. As a consequence, the 
selection of the mucosal alterations of the small bowel deserving investigation is now committed to 
experts judgement. In the patients followed at the two referral Centers involved in this series, in the 
case of ulcers, protruding mucosal alterations, irregular distribution of atrophy features, a 
histological study was planned. In the RCD II cases, biopsies from DBE gave negative results for an 
underlying lymphoproliferative disorder. After exclusion of malignant complications, RCD 
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diagnosis was confirmed and steroid therapy was prescribed; no cases  of intestinal lymphoma 
developed during follow up.  
Ulcerative-type alterations were observed in patients with both polyclonal and monoclonal TCR 
gamma rearrangement, in line with the low specificity of some endoscopic findings.  
In those cases investigated due to poor adherence to GFD or persistence of symptoms while on a 
still short lasting GFD, endoscopic features of atrophy were described with a patchy distribution. 
Biopsies during DBE ruled out complications other than atrophy in association with this mucosal 
pattern. The observation could shed some light on the endoscopic picture of the reversal process 
taking place in the SB of treated CD patients.  
The present study is limited by its retrospective design. However, since evidence-proven criteria for 
the selection of endoscopic findings deserving DAE are lacking, the experience of two tertiary 
referral centers is reported. Comparison with a control CD group was only feasible as far as 
demographical data is concerned; DBE data were obtainable, as is evident, only from cases with 
presumed complicated course. High number of procedures and heterogeneity of indications mainly 
derives from present inaccurate definition of SB endoscopic findings suspected for concealing 
clinically relevant pathological processes. 
Overall, in this large series DBE was proven to be useful in selected CD cases to exclude/confirm 
malignant or premalignant conditions, possibly associated with even minor mucosal lesions. 
Furthermore, DBE altered clinical  management in about one third of  patients. “Negative” 
histological findings resulted also useful  to influence therapeutic decisions in a relevant subset of 
patients. Ongoing research about the identification of clinical factors and endoscopic findings 
associated with a higher risk of neoplastic evolution in CD will address appropriate indications to 
DBE and early diagnosis.  
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5. miRNAs AS POSSIBLE BIOMARKERS OF ENTEROPATHY-ASSOCIATED T CELL 
LYMPHOMA DEVELOPMENT IN CELIAC  DISEASE 
 
5.1 Introduction 
Refractory CD is associated with an increased risk of EATL, representing an “intermediate” state 
between intestinal atrophy and lymphoma. A subset of non-refractory CD patients presents an 
increased neoplastic risk as well. The identification of “at risk CD subjects” with novel biomarkers 
could be pivotal in the selection of patients to be carefully managed for the early detection of SB 
malignancy. This plan is actually hindered by the absence of such a biological marker, except for 
the analysis of TCR gamma rearrangements for the classification of refractoriness   
MicroRNAs (miRNAs) are small noncoding RNAs regulators of gene expression with a role in 
several immune mediated and neoplastic processes with potential diagnostic, prognostic and 
therapeutic implications. We previously reported how different clinical phenotypes of CD display 
unique miRNA signatures.[102]  The discovery of EATL molecular biomarkers useful to stratify 
CD patients according to their neoplastic risk could allow to pursue a “personalized medicine” 
approach. Our hypothesis is that miRNAs through the regulation of gene expression may play a role 
in immune response and carcinogenesis in CD, as demonstrated in other inflammatory, autoimmune 
and neoplastic conditions.[103] Identification of the presence of such biomarkers in association 
with EATL could shed light on the molecular pathogenesis of this malignancy, therefore improving 
our understanding of neoplastic transformation of inflamed CD mucosa. Moreover, we expect that 
the identified miRNA signatures are differently expressed according to different clinical scenario. 
Since only a limited subgroup of CD patients will develop SB malignant complications, we expect 
to identify an association between higher neoplastic risk, such as the clinical conditions of 
refractory disease, and a subset of miRNAs characteristic of CD-related EATL. The identified 
miRNA signatures could support the identification of other categories of CD patients at risk of 
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neoplasia who deserve an accurate clinical management. Since no data are available regarding 
molecular alterations underpinning neoplastic transformation in RCD patients beside TCR gamma 
rearrangement, this project will provide a novel biomarker predictive of disease aggressiveness to 
support a timely pharmacological intervention.  
Moreover, small bowel investigations have been recently ameliorated by the introduction of 
enteroscopy and small bowel targeted imaging techniques. These useful diagnostic tools are costly 
and, often, invasive. Identification of molecular biomarkers associated to the development of 
intestinal lymphoma in CD could lead to targeted selection of the subset of patients deserving an 
accurate evaluation of the small bowel and long term surveillance. The final goal will be to obtain a 
timely diagnosis, a better prognosis and optimization of health resources. 
 
5.2 Methods  
5.2.1 Patients  
Celiac disease and RCD diagnosis was performed in accordance with the international guideline. 
EATL diagnosis was based on the criteria proposed by the WHO Classification of Tumours of 
Haematopoietic and Lymphoid Tissues, Fourth Edition.  
Intestinal samples are from surgical resections in cases of malignancies (EATL) or from endoscopic 
duodenal biopsies (Olympus endoscopes and standard forceps, Boston Scientific) in case of RCD, 
CD or healthy subjects.  
5.2.2 Molecular analyses  
miRNA profiles will be obtained from duodenal mucosa, intra-epithelial infiltrating lymphocytes 
(IEL) or intestinal-associated lymphomas components. Specifically, the aforementioned tissue 
categories will be purified from archival tissue blocks by laser-assisted microdissection (LMD, 
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Leica LMD6000, Leica Microsystems, Milan, Italy) as previously described (Savi et al Clinical 
Science 2014; Vaira et al Oncogene 2012) after identification of the appropriate blocks through 
morphological and histopathological examination. Following a pre-amplification step, miRNA 
expression will be profiled by TaqMan® Low Density Array Human MicroRNA Panel technology 
(Life Technologies, Carlsbad, CA, USA) which enables accurate quantitation of 754 mature 
miRNAs. miRNAs will be then relatively quantified in each sample on reference sno-RNAs (U6, 
RNU44 and RNU48) or on the three most stable transcripts using GeNorm and DataAssist software. 
When the expression of single miRNAs will be analyzed, specific primers and probe for the 
selected target and reference transcripts will be used (TaqMan microRNA assays, Life 
Technologies). 
5.2.3 Statistical analyses 
miRNAs relative quantities will be normalized and log2 transformed before being imported in BRB 
Array Tools software (http://linus.nci.nih.gov/BRB-ArrayTools.html). To identify miRNAs 
specifically associated to CD-EATL, miRNAs will be filtered before being queried by the Class 
comparison and Class prediction analyses. The capacity to discriminate between CD-associated 
EATL from other intestinal lymphomas of the single miRNA or of signatures of miRNAs will be 
then assessed by ROC curves (MedCalc software). 
Selected miRNAs expression will be then verified by single qPCR in the other classes of CD 
patients and ROC curves analysis will be performed to determine specificity and sensibility of the 
biomarker in identifying CD patients at higher risk of neoplastic development.    
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5.3 Preliminary results 
Twenty-seven EATL tissue specimens from 10 CD and 17 non-CD patients, respectively, as well as 
five RCD duodenal biopsies were retrieved from archive of Pathology Division.  
From each EATL case we isolated through laser-assisted microdissection (LMD, Leica LMD6000) 
the lymphoma and the associated epithelial component when available. RCD biopsies were 
extracted in total. Total RNA was then purified using the MasterPure RNA isolation Kit (Epicentre 
Biotechnologies) and quantified spectrophotometrically. Two cases (one from each EATL group) 
were excluded for poor RNA quality. Therefore twenty-five EATL as a whole, 9 from CD patients 
(6 males) and 16 from non-CD patients (5 males) were included in the miRNA profiling study. 
EATL-associated mucosa was available from 7 CD (of which 4 were males) and 10 non-CD 
patients (of which 4 were males).  
Globally, 400 or 448 human miRNAs out of 760 (53% or 59%, respectively) were evaluable in 
EATLs or mucosa tissues of CD related and CD unrelated lymphomas and RCD patients, 
respectively. At unsupervised analysis, miRNA profiles of EATLs did not distinguish patients 
according to celiac disease presence. When supervised analysis was performed (t statistic corrected 
for multiple comparisons) a single miRNA resulted upregulated in CD related EATL (p=0.0002) 
and this data was confirmed at single qPCR analysis (p=0.0012), claiming for a  potential role as 
biomarker of intestinal T cell lymphoma developing in CD. 
When mucosa specimens were evaluated, global miRNA profiling of RCD clearly distinguished 
this class of patients (p=0.001 vs EATL, both CD and non-CD). Moreover, CD patients showed 
similar expression levels when taken as a single group that included RCD and CD related EATL 
and compared to non-CD EATL cases (p=0.001). 
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COMMENTS 
Small bowel malignancies occurring in CD represent rare complications of a widespread disease. 
Despite their low incidence, implementing a secondary prevention strategy is of utmost relevance, 
since the population they can affect is numerous, growing and regularly attending medical attention 
for follow up reasons. Accurate, expensive and sometimes invasive diagnostic tools are presently 
available, but the subset of patients deserving such an approach is partly known.  
Presented data do not support the need to screen general population and asymptomatic subjects in 
order to prevent possible lymphomas. As far as treated CD patients suspected to have a complicated 
course is concerned, endoscopic techniques are useful to detect early intestinal mucosal lesions, 
provided that a better understanding of the clinical relevance of the endoscopic features is achieved. 
Standardized indications to deep enteroscopy and histological sampling are required for  
optimization of health resources. 
Identification of molecular biomarkers, such as miRNA signatures associated to the development of 
intestinal lymphoma in CD could lead to targeted selection of the subset of patients deserving an 
accurate evaluation of the small bowel and long term surveillance. A timely diagnosis will allow 
proposed therapies to be tolerated and prognosis of this subgroup of patients to improve. 
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TABLES 
Table 1. Number and types of Non Hodgkin Lymphoma (NHL) and CD diagnosis in the Varese 
province from 1999 to 2004  
   1999 2000 2001 2002 2003 2004 
NHL (n° of patients) 
     M/F, mean age (years) 
214 
110/104, 
63 
190 
109/81, 60 
173 
92/81, 64 
198 
112/86, 61 
208 
113/95, 64 
197 
107/90, 63 
GI  NHL 
     M/F, mean age (years) 
54 
27/27, 63 
45 
20/25, 63 
30 
16/14, 70 
36 
19/17, 65 
32 
20/12, 69 
40 
18/22, 70 
B-cell lymphoma (any 
site) 
     M/F, mean age (years) 
193 
97/96, 63 
168 
95/73, 61 
154 
82/72, 63 
179 
98/81, 62 
187 
98/89, 64 
165 
93/72, 64 
GI B-cell lymphoma 
     M/F, mean age (years) 
54 
27/27, 63 
45 
20/25, 63 
29 
16/13, 70 
35 
18/17, 65 
30 
19/11, 68 
35 
15/20, 70 
T-cell lymphoma (any 
site) 
     M/F, mean age (years) 
21 
13/8, 62 
22 
14/8, 58 
19 
10/9, 68 
19 
14/5, 57 
21 
15/6, 58 
32 
14/18, 56 
GI T-cell lymphoma 
     M/F, mean age (years) 
0 0 1 
0/1, 77 
1 
1/0, 45 
2 
1/1, 80 
5 
3/2, 65 
Coeliac disease 
     M/F, mean age (years) 
54 
9/45, 35 
48 
16/32, 34 
29 
6/23, 33 
36 
11/25, 31 
59 
15/44, 28 
100 
21/79, 31 
Lymphoma in CD patients 1* 0 0 0 0 0 
*Ki-1+ large cell GI  lymphoma; exclude from data analysis because contemporary diagnosis of CD and 
lymphoma 
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Table 2. Expected cases of Gastrointestinal (GI) B-cell lymphoma in CD patients according to the theoretical 
prevalence of CD in Varese Province 
 Expected cases of GI B-cell Lymphomas (% observed)* 
CD theoretical prevalence 
(number of cases) 
RR = 1 RR = 10 RR = 50 RR = 100 
1: 200 (4076) 0∙19 (0∙5) 1∙91 (5∙0) 9∙57 (25∙2) 19∙15 (50∙4) 
1: 100 (8152) 0∙38 (1∙0) 3∙83 (10∙0) 19∙15 (50∙4) 38∙31 (100∙1) 
1: 50 (16304) 0∙76 (2∙0) 7∙66 (20∙2) 38∙31 (100∙1) 76∙62 (201∙6) 
* incidence of  GI B lymphoma  per 100,000/year in Varese Province = 4∙7 
 
Table 3. Expected cases of Gastrointestinal (GI) T lymphoma in CD patients according to the theoretical 
prevalence of CD in Varese Province 
 Expected cases of GI T-cell Lymphomas (% observed)* 
CD theoretical prevalence 
(number of cases) 
RR = 1 RR = 10 RR = 50 RR = 100 
1: 200 (4076) 0∙008 (0∙5) 0∙08 (5∙4) 0∙40 (27∙1) 0∙81 (54∙3) 
1: 100 (8152) 0∙016 (1∙0) 0∙16 (10∙8) 0∙81 (54∙3) 1∙63 (108∙7) 
1: 50 (16304) 0∙032 (2∙1) 0∙32 (21∙7) 1∙63 (108∙7) 3∙26 (217∙4) 
* incidence of  GI B lymphoma  per 100,000/year in Varese Province = 0∙2 
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Table 4. Risk per 10,000 coeliac patients per year  of  developing a gastrointestinal (GI)  B-cell 
NHL according to the theoretical prevalence of CD and the percentage of coeliac associated 
lymphomas  
 Risk according to the percentage of CD associated GI B cell NHL  
CD theoretical prevalence 
(number of cases) 
100% 50% 25% 1% 
1: 200 (4076) 93∙22 46∙61 23∙30 0∙93 
1: 100 (8152) 46∙61 23∙30 11∙65 0∙46 
1: 50 (16304) 23∙30 11∙65 5∙82 0∙23 
 
Table 5. Risk per 10,000 coeliac patients per year of  developing a gastrointestinal (GI)  T-cell NHL 
according to the theoretical prevalence of CD and the percentage of coeliac associated lymphomas 
 Risk according to the percentage of CD associated GI T cell NHL  
CD theoretical prevalence 
(number of cases) 
100% 50% 25% 1% 
1: 200 (4076) 3∙68 1∙84 0∙92 0∙03 
1: 100 (8152) 1∙84 0∙92 0∙46 0∙02 
1: 50 (16304) 0∙92 0∙46 0∙23 0∙01 
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Table 6. Characteristics of the  celiac patients prospectively evaluated for gastrointestinal tumors 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD, celiac disease; DH dermatitis herpetiformis; RCD, refractory celiac disease. 
 Data are presented as mean±standard deviation; percentages refer to overall number of patients. 
       According to the Marsh-Oberhuber classification.  
 
 
 
Entry criteria   Overall P value 
Positive imaging Non-compliance 
to GFD 
Alarm findings   
Patients, N (%) 7 (7) 16 (15) 82 (78) 105 (100)  
Male sex, N (%) 3 (3) 4 (4) 13 (12) 20 (19) NS 
Age at diagnosis, years 46.7±12 18.9±19.7 42.7±15.6 39.3±18.2 <0.0001 
Age at entry, years 50.6±13.6 37.3±12.4 48.4±13.8 46.8±14.0 <0.005 
CD onset: classic, paucisymptomatic, DH 4, 2, 1 11, 4, 1 58, 22, 2 73, 28, 4 NS 
Positive serology at diagnosis, N (%) 7 (7) 16 (15) 70 (67) 93 (86) P<0.001 
Follow up, years 4.1±5.1 8.8±11.7 5.9±7.1 6.2±7.9 NS 
Positive serology at entry, N (%) 1 (1) 8 (8) 20 (19) 29 (28) NS 
Hemoglobin at enrolment (g/dL) 13.7±1.6 13.7±1.3 11.8±1.9 11.8±2.6 <0.0001 
Duodenal histology at 
entry:0,1,2,3a,3b,3c  
3,-,-,2,-,- -,2,1,5,5,2 23,2,2,22,15,2 26,4,3,29,20,4 NS 
RCD, N (%) 1 (11) 0 11 (10) 12 (11)  
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 Table 7. Characteristics of the 24 celiac patients evaluated with double-balloon enteroscopy due to suspected complicated course 
 Entry criteria    
  RCD GI symptoms 
Sideropenic 
anemia 
Non compliance to 
GFD 
 
Overall P value 
Patients, n 9 6 6 3 24  
Sex, F/M 1/8 4/2 5/1 2/1 12/12  
BMI (kg/cm
2
)
 
20 ± 4 19 ± 2 26 ± 5 23 ± 2 21 ± 4 0.07 
Age, years: at diagnosis 44 ± 19 40 ± 21 25 ± 14 30 ± 15 37 ± 20 0.26 
                    at entry 55 ± 13 46 ± 19 41 ± 15 39 ± 8 47 ± 15 0.25 
CD onset: classic, paucisymptomatic, DH 9, -, - 5, 1, - 1, 5, - 1, 2, -   
Positive serology at diagnosis, n 6 5 6 3   
Follow up, years 11 ± 23 6 ± 13 12 ± 15 9 ± 15 10 ± 17 0.34 
Oral/anal DBE 9/2 2/5 3/3 2/1 16/11  
 
RCD=refractory celiac disease; GI=gastrointestinal; GFD=gluten free diet; BMI=body mass index; CD=celiac disease; DH=dermatitis herpetiformis; DBE=double-balloon 
enteroscopy  
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FIGURES 
Figure 1. Celiac disease (CD) related and CD unrelated enteropathy associated T cell lymphoma (EATL) miRNA profiling: supervised analysis, 
scatterplot (A) and single qPCR analysis of the identified miRNA, under patent (Mann Whitney test, p=0.0012) (B). 
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Figure 2. Mucosa miRNA profiling, supervised analyses, class comparison between three groups: celiac disease (CD) related enteropathy associated 
T cell lymphoma (EATL), CD unrelated EATL, refractory celiac disease (RCD). Global miRNA profiling of RCD clearly distinguished this class of 
patients (p=0.001 vs EATL, both CD and non-CD) 
 
